Modafinil

Modafinil, the active ingredient in Modafinil, is a eugeroic presented as a tablet for oral use. It promotes wakefulness and is prescribed for patients with narcolepsy, obstructive sleep apnea‑related excessive daytime sleepiness, and shift work sleep disorder. GNH USA supplies Modafinil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Modafinil is indicated for disorders of excessive sleepiness that affect daily functioning. - Narcolepsy: reduces daytime sleep attacks and improves alertness. - Obstructive sleep apnea‑related excessive daytime sleepiness: alleviates residual sleepiness despite optimal apnea treatment. - Shift work sleep disorder: helps maintain wakefulness during scheduled work hours.

Modafinil may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Insomnia: difficulty initiating or maintaining sleep. - Dry mouth: reduced salivation. - Anxiety: feelings of nervousness or tension.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Cardiac arrhythmia: irregular heart rhythm, especially in patients with pre‑existing heart disease. - Psychiatric symptoms: hallucinations or severe mood changes. - Severe rash: widespread erythema or blistering.

Before prescribing Modafinil, clinicians should consider several safety factors. - Cardiovascular assessment: evaluate history of hypertension, arrhythmias, or ischemic heart disease. - Psychiatric evaluation: screen for prior psychosis, mania, or severe anxiety. - Liver function: monitor hepatic impairment as metabolism may be affected. - Pregnancy and lactation: avoid use unless benefits clearly outweigh potential risks. - Concomitant CNS stimulants: avoid combining with other wake‑promoting agents. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Modafinil can alter the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - CYP3A4 substrates (e.g., certain statins, oral contraceptives): may reduce efficacy. - CYP2C19 substrates (e.g., proton pump inhibitors): decreased plasma levels.

Moderate Interactions (Monitor Closely): - CYP2B6 substrates (e.g., bupropion): potential increase in plasma concentrations. - Anticoagulants (e.g., warfarin): monitor INR for possible changes. - Antidepressants (e.g., SSRIs): watch for heightened serotonergic effects.